RÉSUMÉ
Acupoint drug delivery is a traditional external therapy of traditional Chinese medicine(TCM). Guided by the meridian and collateral theory in TCM, it applies medications to the skin at acupoints, exerting a dual therapeutic effect by stimulating the acupoints and the conduction of meridians. Acupoint drug delivery is widely used in clinical practice. Different from traditional oral admi-nistration and injection, it absorbs medications through the skin, effectively avoiding the first-pass effect of drugs and the toxic side effects caused by injection. Acupoint selection and transdermal drug absorption are pivotal factors affecting the efficacy of acupoint drug delivery. Recent research on acupoint drug delivery mainly focuses on the evaluation of clinical efficacy, yet the systematic investigations on acupoint selection and pharmacodynamic factors are scarce. This study reviews the mechanism, efficacy evaluation and application status of acupoint drug delivery. It integrates the theory of TCM with modern medicine to explore the mechanism of acupoint drug delivery, evaluate its clinical efficacy, and assess the transdermal penetration in vivo and in vitro. The application status of acupoint drug delivery is also summarized, including the selection of acupoints, application dosage form, application time and the absorption of acupoints. This review aims to offer insights and references for the research, development and clinical application of acupoint drug delivery products.
Sujet(s)
Points d'acupuncture , Systèmes de délivrance de médicaments , Humains , Systèmes de délivrance de médicaments/méthodes , Animaux , Médicaments issus de plantes chinoises/administration et posologie , Médicaments issus de plantes chinoises/pharmacocinétique , Absorption cutanée/effets des médicaments et des substances chimiques , Méridiens , Médecine traditionnelle chinoise , Administration par voie cutanéeRÉSUMÉ
Mortality from cardiovascular disease (CVD) accounts for over 30% of all deaths globally, necessitating reliable diagnostic tools. Prompt identification and precise diagnosis are critical for effective personalized treatment. Nanotechnology offers promising applications in diagnostics, biosensing and drug delivery for prevalent cardiovascular diseases. Its integration into cardiovascular care enhances diagnostic accuracy, enabling early intervention and tailored treatment plans. By leveraging nanoscale innovations, healthcare professionals can address the complexities of CVD progression and customize interventions based on individual patient needs. Ongoing advancements in nanotechnology continue to shape the landscape of cardiovascular medicine, offering potential for improved patient outcomes and reduced mortality rates from these pervasive diseases.
[Box: see text].
Sujet(s)
Marqueurs biologiques , Maladies cardiovasculaires , Nanotechnologie , Humains , Maladies cardiovasculaires/diagnostic , Nanotechnologie/méthodes , Marqueurs biologiques/analyse , Nanomédecine/méthodes , Techniques de biocapteur/méthodes , Systèmes de délivrance de médicaments/méthodesRÉSUMÉ
Transdermal administration techniques have gained popularity due to their advantages over oral and parenteral methods. Noninvasive, self-administered delivery devices improve patient compliance and control drug release. Transdermal delivery devices struggle with the skin's barrier function. Molecules over 500 Dalton (Da) and ionized compounds don't permeate through the skin. Drug encapsulation in phospholipid-based vesicular systems is the most effective skin delivery technique. Vesicular carriers include bi-layered liposomes, ultra-deformable liposomes, ethanolic liposomes, transethosomes, and invasomes. These technologies enhance skin drug permeation by increasing formula solubilization, partitioning into the skin, and fluidizing the lipid barrier. Phospholipid-based delivery systems are safe and efficient, making them a promising pharmaceutical and cosmeceutical drug delivery technique. Still, making delivery systems requires knowledge about the physicochemical properties of the drug and carrier, manufacturing and process variables, skin delivery mechanisms, technological advances, constraints, and regulatory requirements. Consequently, this review covers recent research achievements addressing the mentioned concerns.
Sujet(s)
Administration par voie cutanée , Systèmes de délivrance de médicaments , Liposomes , Phospholipides , Absorption cutanée , Peau , Phospholipides/composition chimique , Humains , Systèmes de délivrance de médicaments/méthodes , Peau/métabolisme , Absorption cutanée/physiologie , Absorption cutanée/effets des médicaments et des substances chimiques , Liposomes/composition chimique , Vecteurs de médicaments/composition chimique , Animaux , Nanoparticules/composition chimiqueRÉSUMÉ
Local anesthesia is essential in dental practices, particularly for managing pain in tooth socket wounds, yet improving drug delivery systems remains a significant challenge. This study explored the physicochemical characteristics of lidocaine hydrochloride (LH) incorporated into a polyelectrolyte complex and poloxamer thermosensitivity hydrogel, assessing its local anesthetic efficacy in mouse models and its onset and duration of action as topical anesthetics in clinical trials. The thermoresponsive hydrogel exhibited a rapid phase transition within 1-3 minutes and demonstrated pseudo-plastic flow behavior. Its release kinetics followed Korsmeyer-Peppas, with 50% of biodegradation occurring over 48 h. In mouse models, certain thermogels showed superior anesthetic effects, with rapid onset and prolonged action, as evidenced by heat tolerance in tail-flick and hot plate models. In clinical trials, the LH-loaded thermoresponsive hydrogel provided rapid numbness onset, with anesthesia (Ton) beginning at an average of 46.5 ± 22.5 seconds and lasting effectively (Teff) for 202.5 ± 41.0 seconds, ranging from 120 to 240 seconds, indicating sustained release. These results highlight the promising properties of these formulations: rapid onset, prolonged duration, mucoadhesion, biodegradability, and high anesthesia effectiveness. This study demonstrates the potential for advancing local anesthesia across various medical fields, emphasizing the synergy between material science and clinical applications to improve patient care and safety.
Sujet(s)
Anesthésiques locaux , Systèmes de délivrance de médicaments , Hydrogels , Lidocaïne , Poloxamère , Lidocaïne/administration et posologie , Lidocaïne/composition chimique , Animaux , Hydrogels/composition chimique , Anesthésiques locaux/administration et posologie , Anesthésiques locaux/composition chimique , Souris , Poloxamère/composition chimique , Systèmes de délivrance de médicaments/méthodes , Polyélectrolytes/composition chimique , Mâle , Libération de médicament , Humains , Préparations à action retardée/administration et posologie , Préparations à action retardée/pharmacocinétiqueRÉSUMÉ
Nanovaccines have been designed to overcome the limitations associated with conventional vaccines. Effective delivery methods such as engineered carriers or smart nanoparticles (NPs) are critical requisites for inducing self-tolerance and optimizing vaccine immunogenicity with minimum side effects. NPs can be used as adjuvants, immunogens, or nanocarriers to develop nanovaccines for efficient antigen delivery. Multiloaded nanovaccines carrying multiple tumor antigens along with immunostimulants can effectively increase immunity against tumor cells. They can be biologically engineered to boost interactions with dendritic cells and to allow a gradual and constant antigen release. Modifying NPs surface properties, using high-density lipoprotein-mimicking nanodiscs, and developing nano-based artificial antigen-presenting cells such as dendritic cell-derived-exosomes are amongst the new developed technologies to enhance antigen-presentation and immune reactions against tumor cells. The present review provides an overview on the different perspectives, improvements, and barriers of successful clinical application of current cancer therapeutic and vaccination options. The immunomodulatory effects of different types of nanovaccines and the nanoparticles incorporated into their structure are described. The advantages of using nanovaccines to prevent and treat common illnesses such as AIDS, malaria, cancer and tuberculosis are discussed. Further, potential paths to develop optimal cancer vaccines are described. Given the immunosuppressive characteristics of both cancer cells and the tumor microenvironment, applying immunomodulators and immune checkpoint inhibitors in combination with other conventional anticancer therapies are necessary to boost the effectiveness of the immune response.
Sujet(s)
Antigènes néoplasiques , Vaccins anticancéreux , Immunothérapie , Nanoparticules , Tumeurs , Humains , Immunothérapie/méthodes , Tumeurs/immunologie , Tumeurs/thérapie , Tumeurs/traitement médicamenteux , Nanoparticules/administration et posologie , Vaccins anticancéreux/administration et posologie , Vaccins anticancéreux/immunologie , Antigènes néoplasiques/immunologie , Antigènes néoplasiques/administration et posologie , Animaux , Association thérapeutique , Systèmes de délivrance de médicaments/méthodes ,RÉSUMÉ
The terpolymers of N-vinylpyrrolidone (VP) with acrylic acid and triethylene glycol methacrylate were synthesized with more than 90% yield by radical copolymerization in ethanol from monomeric mixtures of different molar composition (98:2:2, 95:5: 2 and 98:2:5) and their monomer composition, absolute molecular masses and hydrodynamic radii in aqueous media were determined. Using the MTT test, these terpolymers were established to be low toxic for non-tumor Vero cells and HeLa tumor cells. Polymer compositions of hydrophobic dye methyl pheophorbide a (MPP) based on studied terpolymers and linear polyvinylpyrrolidone (PVP) were obtained and characterized in water solution. Quantum-chemical modeling of the MPP-copolymer structures was conducted, and the possibility of hydrogen bond formation between terpolymer units and the MPP molecule was shown. Using fluorescence microscopy, the accumulation and distribution of polymer particles in non-tumor (FetMSC) and tumor (HeLa) cells was studied, and an increase in the accumulation of MPP with both types of particles was found.
Sujet(s)
Acrylates , Humains , Animaux , Chlorocebus aethiops , Acrylates/composition chimique , Cellules Vero , Cellules HeLa , Systèmes de délivrance de médicaments , Pyrrolidones/composition chimique , Méthacrylates/composition chimique , Polyéthylène glycols/composition chimique , Polymères/composition chimique , Polymères/synthèse chimique , Survie cellulaire/effets des médicaments et des substances chimiquesRÉSUMÉ
Fludarabine (FA) is still considered as a first-line chemotherapy drug for hematological tumors related to B lymphocytes. However, it is worth noting that the non-specific distribution and non-different cytotoxicity of FA may lead to irreversible consequences such as central nervous system damage such as blindness, coma, and even death. Therefore, it is very important to develop a system to targeting delivery FA. In preliminary studies, it was found that B lymphoma cells would specific highly expressing the sialic acid-binding immunoglobulin-like lectin 2 (known as CD22). Inspired by the specific recognition of sialic acid residues and CD22, we have developed a supramolecular prodrug based on polysialic acid, an endogenous biomacromolecule, achieving targeted-therapy of B-cell non-Hodgkin's lymphoma (B-NHL). Specifically, the prepared hydrophobic reactive oxygen species-responsive FA dimeric prodrug (F2A) interacts with the TPSA, which polysialic acid were modified by the thymidine derivatives, through non-covalent intermolecular interactions similar to "Watson-Crick" base pairing, resulting in the formation of nanoscale supramolecular prodrug (F@TPSA). Cell experiments have confirmed that F@TPSA can be endocytosed by CD22+ B lymphoma cells including Raji and Ramos cells, and there is a significant difference of endocytosis in other leukocytes. Furthermore, in B-NHL mouse model, compared with FA, F@TPSA is determined to have a stronger tumor targeting and inhibitory effect. More importantly, the distribution of F@TPSA in vivo tends to be enriched in lymphoma tissue rather than nonspecific, thus reducing the leukopenia of FA. The targeted delivery system based on PSA provides a new prodrug modification strategy for targeted treatment of B-NHL.
Sujet(s)
Lymphome B , Promédicaments , Promédicaments/composition chimique , Promédicaments/pharmacologie , Animaux , Souris , Humains , Lignée cellulaire tumorale , Lymphome B/traitement médicamenteux , Acides sialiques/composition chimique , Acides sialiques/pharmacologie , Lectine-2 de type Ig liant l'acide sialique , Antinéoplasiques/pharmacologie , Antinéoplasiques/composition chimique , Nanoparticules/composition chimique , Médecine de précision/méthodes , Systèmes de délivrance de médicaments/méthodes , Souris de lignée BALB C , Espèces réactives de l'oxygène/métabolisme , Lymphome malin non hodgkinien/traitement médicamenteuxRÉSUMÉ
Helicobacter pylori infection is involved in gastric diseases such as peptic ulcer and adenocarcinoma. Approved antibiotherapies still fail in 10 to 40% of the infected patients and, in this scenario, targeted nanotherapeutics emerged as powerful allies for H. pylori eradication. Nano/microparticles conjugated with H. pylori binding molecules were developed to eliminate H. pylori by either (i) blocking essential mechanisms of infection, such as adhesion to gastric mucosa or (ii) binding and killing H. pylori through the release of drugs within the bacteria or at the site of infection. Glycan antigens (as Lewis B and sialyl-Lewis X), pectins, lectins, phosphatidylethanolamine and epithelial cell membranes were conjugated with nano/microparticles to successfully block H. pylori adhesion. Urea-coated nanoparticles were used to improve drug delivery inside bacteria through H. pylori UreI channel. Moreover, nanoparticles coated with antibodies against H. pylori and loaded with sono/photosensitizers, were promising for their application as targeted sono/photodynamic therapies. Further, non-specific H. pylori nano/microparticles, but only active in the acidic gastric environment, coated with binders to bacterial membrane, extracellular polymeric substances or to high temperature requirement A protease, were evaluated. In this review, an overview of the existing nanotherapeutics targeting H. pylori will be given and their rational, potential to counteract infection, as well as level of development will be presented and discussed.
Sujet(s)
Infections à Helicobacter , Helicobacter pylori , Helicobacter pylori/effets des médicaments et des substances chimiques , Infections à Helicobacter/traitement médicamenteux , Humains , Nanoparticules/usage thérapeutique , Systèmes de délivrance de médicaments/méthodes , Antibactériens/pharmacologie , Antibactériens/usage thérapeutiqueRÉSUMÉ
Purpose: Mitochondrial damage may lead to uncontrolled oxidative stress and massive apoptosis, and thus plays a pivotal role in the pathological processes of myocardial ischemia-reperfusion (I/R) injury. However, it is difficult for the drugs such as puerarin (PUE) to reach the mitochondrial lesion due to lack of targeting ability, which seriously affects the expected efficacy of drug therapy for myocardial I/R injury. Methods: We prepared triphenylphosphonium (TPP) cations and ischemic myocardium-targeting peptide (IMTP) co-modified puerarin-loaded liposomes (PUE@T/I-L), which effectively deliver the drug to mitochondria and improve the effectiveness of PUE in reducing myocardial I/R injury. Results: In vitro test results showed that PUE@T/I-L had sustained release and excellent hemocompatibility. Fluorescence test results showed that TPP cations and IMTP double-modified liposomes (T/I-L) enhanced the intracellular uptake, escaped lysosomal capture and promoted drug targeting into the mitochondria. Notably, PUE@T/I-L inhibited the opening of the mitochondrial permeability transition pore, reduced intracellular reactive oxygen species (ROS) levels and increased superoxide dismutase (SOD) levels, thereby decreasing the percentage of Hoechst-positive cells and improving the survival of hypoxia-reoxygenated (H/R)-injured H9c2 cells. In a mouse myocardial I/R injury model, PUE@T/I-L showed a significant myocardial protective effect against myocardial I/R injury by protecting mitochondrial integrity, reducing myocardial apoptosis and decreasing infarct size. Conclusion: This drug delivery system exhibited excellent mitochondrial targeting and reduction of myocardial apoptosis, which endowed it with good potential extension value in the precise treatment of myocardial I/R injury.
Sujet(s)
Isoflavones , Liposomes , Lésion de reperfusion myocardique , Composés organiques du phosphore , Animaux , Liposomes/composition chimique , Lésion de reperfusion myocardique/traitement médicamenteux , Isoflavones/composition chimique , Isoflavones/pharmacologie , Isoflavones/administration et posologie , Isoflavones/pharmacocinétique , Composés organiques du phosphore/composition chimique , Composés organiques du phosphore/pharmacologie , Composés organiques du phosphore/administration et posologie , Composés organiques du phosphore/pharmacocinétique , Mâle , Souris , Apoptose/effets des médicaments et des substances chimiques , Espèces réactives de l'oxygène/métabolisme , Cations/composition chimique , Myocarde/anatomopathologie , Myocarde/métabolisme , Stress oxydatif/effets des médicaments et des substances chimiques , Peptides/composition chimique , Peptides/pharmacologie , Peptides/administration et posologie , Systèmes de délivrance de médicaments/méthodesRÉSUMÉ
Purpose: Chemotherapy mediated by Reactive oxygen species (ROS)-responsive drug delivery systems can potentially mitigate the toxic side effects of chemotherapeutic drugs and significantly enhance their therapeutic efficacy. However, achieving precise targeted drug delivery and real-time control of ROS-responsive drug release at tumor sites remains a formidable challenge. Therefore, this study aimed to describe a ROS-responsive drug delivery system with specific tumor targeting capabilities for mitigating chemotherapy-induced toxicity while enhancing therapeutic efficacy under guidance of Fluorescence (FL) and Magnetic resonance (MR) bimodal imaging. Methods: Indocyanine green (ICG), Doxorubicin (DOX) prodrug pB-DOX and Superparamagnetic iron oxide (SPIO, Fe3O4) were encapsulated in poly(lactic-co-glycolic acid) (PLGA) by double emulsification method to prepare ICG/ pB-DOX/ Fe3O4/ PLGA nanoparticles (IBFP NPs). The surface of IBFP NPs was functionalized with mammaglobin antibodies (mAbs) by carbodiimide method to construct the breast cancer-targeting mAbs/ IBFP NPs (MIBFP NPs). Thereafter, FL and MR bimodal imaging ability of MIBFP NPs was evaluated in vitro and in vivo. Finally, the combined photodynamic therapy (PDT) and chemotherapy efficacy evaluation based on MIBFP NPs was studied. Results: The multifunctional MIBFP NPs exhibited significant targeting efficacy for breast cancer. FL and MR bimodal imaging clearly displayed the distribution of the targeting MIBFP NPs in vivo. Upon near-infrared laser irradiation, the MIBFP NPs loaded with ICG effectively generated ROS for PDT, enabling precise tumor ablation. Simultaneously, it triggered activation of the pB-DOX by cleaving its sensitive moiety, thereby restoring DOX activity and achieving ROS-responsive targeted chemotherapy. Furthermore, the MIBFP NPs combined PDT and chemotherapy to enhance the efficiency of tumor ablation under guidance of bimodal imaging. Conclusion: MIBFP NPs constitute a novel dual-modality imaging-guided drug delivery system for targeted breast cancer therapy and offer precise and controlled combined treatment options.
Sujet(s)
Tumeurs du sein , Doxorubicine , Vert indocyanine , Imagerie par résonance magnétique , Photothérapie dynamique , Copolymère d'acide poly(lactique-co-glycolique) , Espèces réactives de l'oxygène , Vert indocyanine/composition chimique , Vert indocyanine/pharmacocinétique , Doxorubicine/composition chimique , Doxorubicine/pharmacologie , Doxorubicine/administration et posologie , Doxorubicine/pharmacocinétique , Espèces réactives de l'oxygène/métabolisme , Animaux , Femelle , Humains , Copolymère d'acide poly(lactique-co-glycolique)/composition chimique , Photothérapie dynamique/méthodes , Tumeurs du sein/imagerie diagnostique , Tumeurs du sein/traitement médicamenteux , Tumeurs du sein/métabolisme , Imagerie par résonance magnétique/méthodes , Souris , Lignée cellulaire tumorale , Systèmes de délivrance de médicaments/méthodes , Promédicaments/composition chimique , Promédicaments/pharmacocinétique , Promédicaments/pharmacologie , Souris de lignée BALB C , Nanoparticules magnétiques d'oxyde de fer/composition chimique , Souris nude , Nanoparticules de magnétite/composition chimique , Libération de médicament , Nanoparticules/composition chimique , Imagerie optique/méthodesRÉSUMÉ
Objective: Nanomedicine represents a transformative approach in biomedical applications. This study aims to delineate the application of nanomedicine in the biomedical field through the strengths, weaknesses, opportunities, and threats (SWOT) analysis to evaluate its efficacy and potential in clinical applications. Methods: The SWOT analysis framework was employed to systematically review and assess the internal strengths and weaknesses, along with external opportunities and threats of nanomedicine. This method provides a balanced consideration of the potential benefits and challenges. Results: Findings from the SWOT analysis indicate that nanomedicine presents significant potential in drug delivery, diagnostic imaging, and tissue engineering. Nonetheless, it faces substantial hurdles such as safety issues, environmental concerns, and high development costs. Critical areas for development were identified, particularly concerning its therapeutic potential and the uncertainties surrounding long-term effects. Conclusion: Nanomedicine holds substantial promise in driving medical innovation. However, successful clinical translation requires addressing safety, cost, and regulatory challenges. Interdisciplinary collaboration and comprehensive strategic planning are crucial for the safe and effective application of nanomedicine.
Sujet(s)
Systèmes de délivrance de médicaments , Nanomédecine , Humains , Ingénierie tissulaireRÉSUMÉ
INTRODUCTION: Esophageal cancer is one of the major cancers in China. Most patients with esophageal cancer are diagnosed at an advanced stage, and the 5 year survival rate is discouraging. Combined chemotherapy is a common method for the treatment of esophageal cancer. METHODS: In this study, distearoyl phosphatidyl ethanolamine polyethylene glycol 2000 (DSPE-PEG2000) nanoliposomes (NLPs) encapsulating the anticancer drugs docetaxel (DOX) and oridonin (ORD) were prepared, and their ability to enhance the release of anticancer drugs was determined. The NLP system was characterized by transmission electron microscopy, particle size and encapsulation efficiency. In addition, the release characteristics and pharmacodynamics of these drugs were also studied in detail. RESULTS: When the DOX/ORD ratio was 2:1, the higher proportion of DOX led to a stronger synergy effect. DOX/ORD NLPs were prepared by the high-pressure homogenization method and had a uniform spherical morphology. The mean particle size and polydispersity index were determined to be 246.4 and 0.163, respectively. The stability results showed that no significant change was observed in particle size, zeta potential, Encapsulation efficiency and dynamic light scattering for DOX/ORD NLPs during the observation period. The results of in vitro release illustrated that the acidic environment of tumor might be beneficial to drug release. The three-dimensional tumorsphere showed that DOX/ORD NLPs can reach the interior of tumor spheres, which destroys the structure of cells, resulting in irregular spherical tumor spheres. The in vivo study results indicated that DOX/ORD NLPs had an obvious targeting effect on subcutaneous tumors and have the potential to actively deliver drugs to tumor tissues. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining was used to detect apoptosis. The results showed that DOX/ORD NLP treatment could significantly induce apoptosis and inhibit tumor growth. CONCLUSION: The DOX/ORD NLPs prepared in this study can enhance the anti-tumor activity, and are expected to be a promising co-delivery platform for the treatment of esophageal cancer.
Sujet(s)
Diterpènes de type kaurane , Docetaxel , Tumeurs de l'oesophage , Liposomes , Diterpènes de type kaurane/pharmacologie , Diterpènes de type kaurane/composition chimique , Diterpènes de type kaurane/administration et posologie , Tumeurs de l'oesophage/traitement médicamenteux , Tumeurs de l'oesophage/anatomopathologie , Docetaxel/pharmacologie , Docetaxel/administration et posologie , Docetaxel/composition chimique , Liposomes/composition chimique , Animaux , Humains , Lignée cellulaire tumorale , Souris , Antinéoplasiques/pharmacologie , Antinéoplasiques/administration et posologie , Antinéoplasiques/composition chimique , Nanoparticules/composition chimique , Taille de particule , Tests d'activité antitumorale sur modèle de xénogreffe , Libération de médicament , Systèmes de délivrance de médicaments/méthodes , Souris nude , Souris de lignée BALB C , Système d'administration de médicaments à base de nanoparticules/composition chimiqueRÉSUMÉ
Due to its chronic nature and complex pathophysiology, inflammatory bowel disease (IBD) poses significant challenges for treatment. The long-term therapies for patients, often diagnosed between the ages of 20 and 40, call for innovative strategies to target inflammation, minimize systemic drug exposure, and improve patients' therapeutic outcomes. Among the plethora of strategies currently pursued, bioinspired and bioderived nano-based formulations have garnered interest for their safety and versatility in the management of IBD. Bioinspired nanomedicine can host and deliver not only small drug molecules but also biotherapeutics, be made gastroresistant and mucoadhesive or mucopenetrating and, for these reasons, are largely investigated for oral administration, while surprisingly less for rectal delivery, recommended first-line treatment approach for several IBD patients. The use of bioderived nanocarriers, mostly extracellular vesicles (EVs), endowed with unique homing abilities, is still in its infancy with respect to the arsenal of nanomedicine under investigation for IBD treatment. An emerging source of EVs suited for oral administration is ingesta, that is, plants or milk, thanks to their remarkable ability to resist the harsh environment of the upper gastrointestinal tract. Inspired by the unparalleled properties of natural biomaterials, sophisticated avenues for enhancing therapeutic efficacy and advancing precision medicine approaches in IBD care are taking shape, although bottlenecks arising either from the complexity of the nanomedicine designed or from the lack of a clear regulatory pathway still hinder a smooth and efficient translation to the clinics. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology.
Sujet(s)
Maladies inflammatoires intestinales , Nanomédecine , Humains , Maladies inflammatoires intestinales/traitement médicamenteux , Animaux , Vésicules extracellulaires/métabolisme , Systèmes de délivrance de médicaments , SourisRÉSUMÉ
Topical therapy remains a critical component in the management of immunemediated inflammatory dermatoses such as psoriasis and atopic dermatitis. In this field, macrolactam immunomodulators, including calcineurin and mammalian target of rapamycin inhibitors, can offer steroidfree therapeutic alternatives. Despite their potential for skinselective treatment compared with topical corticosteroids, the physicochemical properties of these compounds, such as high lipophilicity and large molecular size, do not meet the criteria for efficient penetration into the skin, especially with conventional topical vehicles. Thus, more sophisticated approaches are needed to address the pharmacokinetic limitations of traditional formulations. In this regard, interest has increasingly focused on nanoparticulate systems to optimize penetration kinetics and enhance the efficacy and safety of topical calcineurin and mTOR inhibitors in inflamed skin. Several types of nanovectors have been explored as topical carriers to deliver tacrolimus in both psoriatic and atopic skin, while preclinical data on nanocarrierbased delivery of topical sirolimus in inflamed skin are also emerging. Given the promising preliminary outcomes and the complexities of drug delivery across inflamed skin, further research is required to translate these nanotherapeutics into clinical settings for inflammatory skin diseases. The present review outlined the dermatokinetic profiles of topical calcineurin and mTOR inhibitors, particularly tacrolimus, pimecrolimus and sirolimus, focusing on their penetration kinetics in psoriatic and atopic skin. It also summarizes the potential antiinflammatory benefits of topical sirolimus and explores novel preclinical studies investigating dermally applied nanovehicles to evaluate and optimize the skin delivery, efficacy and safety of these 'hardtoformulate' macromolecules in the context of psoriasis and atopic dermatitis.
Sujet(s)
Inhibiteurs de la calcineurine , Inhibiteurs de mTOR , Humains , Inhibiteurs de la calcineurine/usage thérapeutique , Animaux , Inhibiteurs de mTOR/usage thérapeutique , Administration par voie topique , Nanotechnologie/méthodes , Eczéma atopique/traitement médicamenteux , Nanoparticules/composition chimique , Tacrolimus/usage thérapeutique , Tacrolimus/administration et posologie , Tacrolimus/pharmacologie , Sirolimus/usage thérapeutique , Sirolimus/pharmacologie , Systèmes de délivrance de médicaments/méthodesRÉSUMÉ
Metformin, the primary therapy for type 2 diabetes mellitus (T2DM), showed limitations such as varying absorption, rapid system clearance, required large amount, resistance, longstanding side effects. Use of Nano formulations for pharmaceuticals is emerging as a viable technique to reduce negative consequences of drug, while simultaneously attaining precise release and targeted distribution. This study developed a Polyethylene Glycol conjugated Graphene Oxide Quantum dots (GOQD-PEG) nanocomposite for the sustained release of metformin. Herein, we evaluated the effectiveness of metformin-loaded nanoconjugate in in vitro insulin resistance model. Results demonstrated drug loaded nanoconjugate successfully restored glucose uptake and reversed insulin resistance in in vitro conditions at reduced dosage compared to free metformin.
Sujet(s)
Préparations à action retardée , Graphite , Insulinorésistance , Metformine , Nanoconjugués , Polyéthylène glycols , Boîtes quantiques , Graphite/composition chimique , Boîtes quantiques/composition chimique , Metformine/administration et posologie , Metformine/pharmacologie , Metformine/pharmacocinétique , Metformine/composition chimique , Polyéthylène glycols/composition chimique , Nanoconjugués/composition chimique , Préparations à action retardée/composition chimique , Préparations à action retardée/pharmacocinétique , Humains , Hypoglycémiants/administration et posologie , Hypoglycémiants/pharmacologie , Hypoglycémiants/composition chimique , Systèmes de délivrance de médicaments , Diabète de type 2/traitement médicamenteux , Glucose/métabolisme , Glucose/composition chimiqueRÉSUMÉ
BACKGROUND: Colorectal cancer is a common disease worldwide with non-specific symptoms such as blood in the stool, bowel movements, weight loss and fatigue. Chemotherapy drugs can cause side effects such as nausea, vomiting and a weakened immune system. The use of antioxidants such as hesperidin could reduce the side effects, but its low bioavailability is a major problem. In this research, we aimed to explore the drug delivery and efficiency of this antioxidant on the HCT116 colorectal cancer cell line by loading hesperidin into PLGA nanoparticles. MATERIALS AND METHODS: Hesperidin loaded PLGA nanoparticles were produced by single emulsion evaporation method. The physicochemical properties of the synthesized hesperidin-loaded nanoparticles were determined using SEM, AFM, FT-IR, DLS and UV-Vis. Subsequently, the effect of the PLGA loaded hesperidin nanoparticles on the HCT116 cell line after 48 h was investigated by MTT assay at three different concentrations of the nanoparticles. RESULT: The study showed that 90% of hesperidin were loaded in PLGA nanoparticles by UV-Vis spectrophotometry and FT-IR spectrum. The nanoparticles were found to be spherical and uniform with a hydrodynamic diameter of 76.2 nm in water. The release rate of the drug was about 93% after 144 h. The lowest percentage of cell viability of cancer cells was observed at a concentration of 10 µg/ml of PLGA nanoparticles loaded with hesperidin. CONCLUSION: The results indicate that PLGA nanoparticles loaded with hesperidin effectively reduce the survival rate of HCT116 colorectal cancer cells. However, further studies are needed to determine the appropriate therapeutic dosage and to conduct animal and clinical studies.
Sujet(s)
Tumeurs colorectales , Hespéridine , Nanoparticules , Copolymère d'acide poly(lactique-co-glycolique) , Humains , Hespéridine/composition chimique , Hespéridine/pharmacologie , Hespéridine/administration et posologie , Copolymère d'acide poly(lactique-co-glycolique)/composition chimique , Tumeurs colorectales/traitement médicamenteux , Cellules HCT116 , Nanoparticules/composition chimique , Survie cellulaire/effets des médicaments et des substances chimiques , Acide lactique/composition chimique , Acide polyglycolique/composition chimique , Systèmes de délivrance de médicaments , Taille de particule , Vecteurs de médicaments/composition chimique , Spectroscopie infrarouge à transformée de Fourier , Antinéoplasiques/pharmacologie , Antinéoplasiques/composition chimique , Système d'administration de médicaments à base de nanoparticules/composition chimiqueRÉSUMÉ
Neurodegenerative disorders are complex, progressive, and life-threatening. They cause mortality and disability for millions of people worldwide. Appropriate treatment for neurodegenerative diseases (NDs) is still clinically lacking due to the presence of the blood-brain barrier (BBB). Developing an effective transport system that can cross the BBB and enhance the therapeutic effect of neuroprotective agents has been a major challenge for NDs. Exosomes are endogenous nano-sized vesicles that naturally carry biomolecular cargoes. Many studies have indicated that exosome content, particularly microRNAs (miRNAs), possess biological activities by targeting several signaling pathways involved in apoptosis, inflammation, autophagy, and oxidative stress. Exosome content can influence cellular function in healthy or pathological ways. Furthermore, since exosomes reflect the features of the parental cells, their cargoes offer opportunities for early diagnosis and therapeutic intervention of diseases. Exosomes have unique characteristics that make them ideal for delivering drugs directly to the brain. These characteristics include the ability to pass through the BBB, biocompatibility, stability, and innate targeting properties. This review emphasizes the role of exosomes in alleviating NDs and discusses the associated signaling pathways and molecular mechanisms. Furthermore, the unique biological features of exosomes, making them a promising natural transporter for delivering various medications to the brain to combat several NDs, are also discussed.
Sujet(s)
Barrière hémato-encéphalique , Systèmes de délivrance de médicaments , Exosomes , Maladies neurodégénératives , Exosomes/métabolisme , Humains , Maladies neurodégénératives/traitement médicamenteux , Maladies neurodégénératives/métabolisme , Barrière hémato-encéphalique/métabolisme , Barrière hémato-encéphalique/effets des médicaments et des substances chimiques , Animaux , Systèmes de délivrance de médicaments/méthodes , Neuroprotecteurs/usage thérapeutique , Neuroprotecteurs/pharmacologie , microARN/métabolisme , Transduction du signal/effets des médicaments et des substances chimiques , Vecteurs de médicaments/composition chimiqueRÉSUMÉ
Background: At present, the few photothermal/chemotherapy studies about retinoblastoma that have been reported are mainly restricted to ectopic models involving subcutaneous implantation. However, eyeball is unique physiological structure, the blood-retina barrier (BRB) hinders the absorption of drug molecules through the systemic route. Moreover, the abundant blood circulation in the fundus accelerates drug metabolism. To uphold the required drug concentration, patients must undergo frequent chemotherapy sessions. Purpose: To address these challenges above, we need to develop a secure and effective drug delivery system (FA-PEG-PDA-DOX) for the fundus. Methods: We offered superior therapeutic efficacy with minimal or no side effects and successfully established orthotopic mouse models. We evaluated cellular uptake performance and targeting efficiency of FA-PEG-PDA-DOX nanosystem and assessed its synergistic antitumor effects in vitro and vivo. Biodistribution assessments were performed to determine the retention time and targeting efficiency of the NPs in vivo. Additionally, safety assessments were conducted. Results: Cell endocytosis rates of the FA-PEG-PDA-DOX+Laser group became 5.23 times that of the DOX group and 2.28 times that of FA-PEG-PDA-DOX group without irradiation. The fluorescence signal of FA-PEG-PDA-DOX persisted for more than 120 hours at the tumor site. The number of tumor cells (17.2%) in the proliferative cycle decreased by 61.6% in the photothermal-chemotherapy group, in contrast to that of the saline control group (78.8%). FA-PEG-PDA-DOX nanoparticles(NPs) exhibited favorable biosafety and high biocompatibility. Conclusion: The dual functional targeted nanosystem, with the effects of DOX and mild-temperature elevation by irradiation, resulted in precise chemo/photothermal therapy in nude mice model.
Sujet(s)
Doxorubicine , Indoles , Thérapie photothermique , Polymères , Rétinoblastome , Animaux , Rétinoblastome/thérapie , Doxorubicine/composition chimique , Doxorubicine/pharmacocinétique , Doxorubicine/pharmacologie , Doxorubicine/administration et posologie , Souris , Thérapie photothermique/méthodes , Humains , Indoles/composition chimique , Indoles/pharmacocinétique , Indoles/pharmacologie , Lignée cellulaire tumorale , Polymères/composition chimique , Distribution tissulaire , Polyéthylène glycols/composition chimique , Polyéthylène glycols/pharmacocinétique , Souris nude , Nanoparticules/composition chimique , Systèmes de délivrance de médicaments/méthodes , Tumeurs de la rétine/thérapie , Tumeurs de la rétine/traitement médicamenteux , Souris de lignée BALB C , Antibiotiques antinéoplasiques/pharmacologie , Antibiotiques antinéoplasiques/composition chimique , Antibiotiques antinéoplasiques/pharmacocinétique , Antibiotiques antinéoplasiques/administration et posologie , Modèles animaux de maladie humaine , Tests d'activité antitumorale sur modèle de xénogreffe , Système d'administration de médicaments à base de nanoparticules/composition chimique , Système d'administration de médicaments à base de nanoparticules/pharmacocinétiqueRÉSUMÉ
Psoriasis is an immune-mediated inflammatory skin disease where topical therapy is crucial. While various dosage forms have enhanced the efficacy of current treatments, their limited permeability and lack of targeted delivery to the dermis and epidermis remain challenges. We reviewed the evolution of topical therapies for psoriasis and conducted a bibliometric analysis from 1993 to 2023 using a predictive linear regression model. This included a comprehensive statistical and visual evaluation of each model's validity, literature profiles, citation patterns, and collaborations, assessing R variance and mean squared error (MSE). Furthermore, we detailed the structural features and penetration pathways of emerging drug delivery systems for topical treatment, such as lipid-based, polymer-based, metallic nanocarriers, and nanocrystals, highlighting their advantages. This systematic overview indicates that future research should focus on developing novel drug delivery systems characterized by enhanced stability, biocompatibility, and drug-carrying capacity.
Sujet(s)
Bibliométrie , Systèmes de délivrance de médicaments , Psoriasis , Psoriasis/traitement médicamenteux , Humains , Systèmes de délivrance de médicaments/méthodes , Nanoparticules/composition chimique , Nanoparticules/administration et posologie , Vecteurs de médicaments/composition chimique , Administration par voie topique , Administration par voie cutanée , Produits dermatologiques/administration et posologie , Produits dermatologiques/pharmacocinétique , Produits dermatologiques/composition chimiqueRÉSUMÉ
Ischemic stroke is a serious neurological disease involving multiple complex physiological processes, including vascular obstruction, brain tissue ischemia, impaired energy metabolism, cell death, impaired ion pump function, and inflammatory response. In recent years, there has been significant interest in cell membrane-functionalized biomimetic nanoparticles as a novel therapeutic approach. This review comprehensively explores the mechanisms and importance of using these nanoparticles to treat acute ischemic stroke with a special emphasis on their potential for actively targeting therapies through cell membranes. We provide an overview of the pathophysiology of ischemic stroke and present advances in the study of biomimetic nanoparticles, emphasizing their potential for drug delivery and precision-targeted therapy. This paper focuses on bio-nanoparticles encapsulated in bionic cell membranes to target ischemic stroke treatment. It highlights the mechanism of action and research progress regarding different types of cell membrane-functionalized bi-onic nanoparticles such as erythrocytes, neutrophils, platelets, exosomes, macrophages, and neural stem cells in treating ischemic stroke while emphasizing their potential to improve brain tissue's ischemic state and attenuate neurological damage and dysfunction. Through an in-depth exploration of the potential benefits provided by cell membrane-functionalized biomimetic nanoparticles to improve brain tissue's ischemic state while reducing neurological injury and dysfunction, this study also provides comprehensive research on neural stem cells' potential along with that of cell membrane-functionalized biomimetic nanoparticles to ameliorate neurological injury and dysfunction. However, it is undeniable that there are still some challenges and limitations in terms of biocompatibility, safety, and practical applications for clinical translation.